Literature DB >> 25982527

Structural Insights into the Molecular Recognition between Cerebral Cavernous Malformation 2 and Mitogen-Activated Protein Kinase Kinase Kinase 3.

Xiaoyan Wang1, Yanjie Hou2, Kai Deng3, Ying Zhang2, Da-Cheng Wang4, Jingjin Ding5.   

Abstract

Cerebral cavernous malformation 2 (CCM2) functions as an adaptor protein implicated in various biological processes. By interacting with the mitogen-activated protein kinase MEKK3, CCM2 either mediates the activation of MEKK3 signaling in response to osmotic stress or negatively regulates MEKK3 signaling, which is important for normal cardiovascular development. However, the molecular basis governing CCM2-MEKK3 interaction is largely unknown. Here we report the crystal structure of the CCM2 C-terminal part (CCM2ct) containing both the five-helix domain (CCM2cts) and the following C-terminal tail. The end of the C-terminal tail forms an isolated helix, which interacts intramolecularly with CCM2cts. By biochemical studies we identified the N-terminal amphiphilic helix of MEKK3 (MEKK3-nhelix) as the essential structural element for CCM2ct binding. We further determined the crystal structure of CCM2cts-MEKK3-nhelix complex, in which MEKK3-nhelix binds to the same site of CCM2cts for CCM2ct intramolecular interaction. These findings build a structural framework for understanding CCM2ct-MEKK3 molecular recognition.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25982527     DOI: 10.1016/j.str.2015.04.003

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  12 in total

Review 1.  Cerebrovascular disorders associated with genetic lesions.

Authors:  Philipp Karschnia; Sayoko Nishimura; Angeliki Louvi
Journal:  Cell Mol Life Sci       Date:  2018-10-16       Impact factor: 9.261

2.  Distinct cellular roles for PDCD10 define a gut-brain axis in cerebral cavernous malformation.

Authors:  Alan T Tang; Katie R Sullivan; Courtney C Hong; Lauren M Goddard; Aparna Mahadevan; Aileen Ren; Heidy Pardo; Amy Peiper; Erin Griffin; Ceylan Tanes; Lisa M Mattei; Jisheng Yang; Li Li; Patricia Mericko-Ishizuka; Le Shen; Nicholas Hobson; Romuald Girard; Rhonda Lightle; Thomas Moore; Robert Shenkar; Sean P Polster; Claudia J Roedel; Ning Li; Qin Zhu; Kevin J Whitehead; Xiangjian Zheng; Amy Akers; Leslie Morrison; Helen Kim; Kyle Bittinger; Christopher J Lengner; Markus Schwaninger; Anna Velcich; Leonard Augenlicht; Salim Abdelilah-Seyfried; Wang Min; Douglas A Marchuk; Issam A Awad; Mark L Kahn
Journal:  Sci Transl Med       Date:  2019-11-27       Impact factor: 17.956

3.  SLX4 interacts with RTEL1 to prevent transcription-mediated DNA replication perturbations.

Authors:  A Takedachi; E Despras; S Scaglione; R Guérois; J H Guervilly; M Blin; S Audebert; L Camoin; Z Hasanova; M Schertzer; A Guille; D Churikov; I Callebaut; V Naim; M Chaffanet; J P Borg; F Bertucci; P Revy; D Birnbaum; A Londoño-Vallejo; P L Kannouche; P H L Gaillard
Journal:  Nat Struct Mol Biol       Date:  2020-05-11       Impact factor: 15.369

4.  The cerebral cavernous malformation proteins CCM2L and CCM2 prevent the activation of the MAP kinase MEKK3.

Authors:  Xavier Cullere; Eva Plovie; Paul M Bennett; Calum A MacRae; Tanya N Mayadas
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-04       Impact factor: 11.205

Review 5.  Cerebral Cavernous Malformations: Review of the Genetic and Protein-Protein Interactions Resulting in Disease Pathogenesis.

Authors:  Jacob F Baranoski; M Yashar S Kalani; Colin J Przybylowski; Joseph M Zabramski
Journal:  Front Surg       Date:  2016-11-14

6.  Endothelial TLR4 and the microbiome drive cerebral cavernous malformations.

Authors:  Alan T Tang; Jaesung P Choi; Jonathan J Kotzin; Yiqing Yang; Courtney C Hong; Nicholas Hobson; Romuald Girard; Hussein A Zeineddine; Rhonda Lightle; Thomas Moore; Ying Cao; Robert Shenkar; Mei Chen; Patricia Mericko; Jisheng Yang; Li Li; Ceylan Tanes; Dmytro Kobuley; Urmo Võsa; Kevin J Whitehead; Dean Y Li; Lude Franke; Blaine Hart; Markus Schwaninger; Jorge Henao-Mejia; Leslie Morrison; Helen Kim; Issam A Awad; Xiangjian Zheng; Mark L Kahn
Journal:  Nature       Date:  2017-05-10       Impact factor: 49.962

7.  Cerebral cavernous malformations are driven by ADAMTS5 proteolysis of versican.

Authors:  Courtney C Hong; Alan T Tang; Matthew R Detter; Jaesung P Choi; Rui Wang; Xi Yang; Andrea A Guerrero; Carl F Wittig; Nicholas Hobson; Romuald Girard; Rhonda Lightle; Thomas Moore; Robert Shenkar; Sean P Polster; Lauren M Goddard; Aileen A Ren; N Adrian Leu; Stephanie Sterling; Jisheng Yang; Li Li; Mei Chen; Patricia Mericko-Ishizuka; Lukas E Dow; Hideto Watanabe; Markus Schwaninger; Wang Min; Douglas A Marchuk; Xiangjian Zheng; Issam A Awad; Mark L Kahn
Journal:  J Exp Med       Date:  2020-10-05       Impact factor: 14.307

Review 8.  Cerebral Cavernous Malformation: From Mechanism to Therapy.

Authors:  Daniel A Snellings; Courtney C Hong; Aileen A Ren; Miguel A Lopez-Ramirez; Romuald Girard; Abhinav Srinath; Douglas A Marchuk; Mark H Ginsberg; Issam A Awad; Mark L Kahn
Journal:  Circ Res       Date:  2021-06-24       Impact factor: 23.213

9.  Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signalling.

Authors:  Zinan Zhou; Alan T Tang; Weng-Yew Wong; Sharika Bamezai; Lauren M Goddard; Robert Shenkar; Su Zhou; Jisheng Yang; Alexander C Wright; Matthew Foley; J Simon C Arthur; Kevin J Whitehead; Issam A Awad; Dean Y Li; Xiangjian Zheng; Mark L Kahn
Journal:  Nature       Date:  2016-03-30       Impact factor: 49.962

10.  Two Novel KRIT1 and CCM2 Mutations in Patients Affected by Cerebral Cavernous Malformations: New Information on CCM2 Penetrance.

Authors:  Concetta Scimone; Luigi Donato; Zoe Katsarou; Sevasti Bostantjopoulou; Rosalia D'Angelo; Antonina Sidoti
Journal:  Front Neurol       Date:  2018-11-14       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.